Clinical trial · Interventional
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Estrogens are implicated in the development of ovarian cancer and estrogen receptors (ER) alpha and beta are present in 20-100% of ovarian cancer patients. For this reason, antihormonal therapy with anti-estrogens or ER-antagonists is potentially an attractive treatment option. However, only a small proportion of patients (5-19%) will respond to antihormonal therapy. ER-expression in ER-positive breast cancer can be assessed by positron emission tomography (PET) with \[18F\]fluoroestradiol (FES). In this study the investigators will evaluate whether FES-PET can be used to visualize and quantify ER-expression in ovarian cancer. If these results are positive, this would warrant further exploration of FES-PET imaging in ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FES-PET | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FES-PET
- description
- Patients undergo FES-PET prior to obtaining histology
- interventionNames
- Other: FES-PET
Primary outcomes (1)
- measure
- The feasibility of FES-PET to visualize and quantify ER-positive lesions in epithelial ovarian cancer.
- timeFrame
- approximately 1 month
- description
- Ovarian cancer patients planned for surgery or in which histology/cytology will be obtained, will undergo FES-PET/CT. FES-PET/CT will be qualitatively analyzed to determine whether ovarian cancer lesions can be visualized. FES-uptake will be quantified for all known lesions. Patient material will be stained for ER-expression to determine whether ER-positive metastases show FES-uptake.
Secondary outcomes (2)
- measure
- Correlation between FES-PET and immunohistochemistry (IHC)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histological evidence or high clinical suspicion of epithelial ovarian cancer 2. The presence of at least one measurable lesion (RECIST version 1.1). 3. Histology or cytology can be obtained (may be ascites) 4. Eastern Cooperative Oncology Group performance status 0-2. 5. Postmenopausal status (defined as either \>45 years with amenorrhea \>12 months, or prior bilateral ovariectomy) 6. No history of other ER-positive malignancies 7. Signed written informed consent 8. Able to comply with the protocol Exclusion Criteria: 1. Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, during the 5 weeks before entry into the study 2. Life-expectancy ≤ 3 months
References
Publications (2)
- BACKGROUNDYoshida Y, Kurokawa T, Tsujikawa T, Okazawa H, Kotsuji F. Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET. J Ovarian Res. 2009 Jun 16;2(1):7. doi: 10.1186/1757-2215-2-7. PMID 19527525
- BACKGROUNDPeterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, Gown A, Link JM, Tewson T, Krohn KA. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008 Mar;49(3):367-74. doi: 10.2967/jnumed.107.047506. Epub 2008 Feb 20. PMID 18287268